Palisade Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 207.38M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Details
| Name | Palisade Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 14 |
| Founded | 1996 |
| Ceo | J. Finley |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US6963894026 |
| Cusip | 696389402 |
| Cik | 1357459 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| J. D. Finley | Chief Executive Officer, Chief Financial Officer and Director |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | President and Chief Medical Officer |
Contact
| Address | 4600 South Syracuse Street, Suite 900, Denver, Colorado 80237, United States |
| Phone | 858 704 4900 |
| Website | https://www.palisadebio.com |